Nothing said here yet.
to join the conversation.
| Titterton Lewis H jrDirector | Buy | 8,000 | $23.8K | Fri, Oct 23 |
| KUMAR AMITChief Executive Officer | Buy | 8,000 | $21.8K | Thu, Oct 22 |
| Catelani MichaelPresident, COO, & CFO | Buy | 5,500 | $15.6K | Wed, Sep 30 |
| KUMAR AMITChief Executive Officer | Buy | 7,000 | $19.5K | Thu, Sep 24 |
| Baskies Arnold MDirector | Buy | 5,000 | $13.8K | Thu, Sep 24 |
| Titterton Lewis H jrDirector | Buy | 49,036 | $131.9K | Wed, Sep 23 |
| Titterton Lewis H jrDirector | Buy | 10,000 | $27.3K | Thu, Sep 10 |
| KUMAR AMITChief Executive Officer | Buy | 5,000 | $13.8K | Thu, Sep 10 |
| KUMAR AMITChief Executive Officer | Buy | 3,000 | $8.3K | Thu, Sep 10 |
Learn how Anixa is advancing two clinical-stage oncology programs through differentiated immunotherapy and vaccine approachesManagement to discuss CAR-T clinical progress, completed Phase 1 breast cancer vaccine trial, planned Phase 2 development, and…
First patient in current dose cohort exhibited no progression of her cancer three months after treatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct.
Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct.
ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.
SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr.
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr.
Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth…
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).